Anti-EGFR/anti-4-1BB bispecific antibody
US12168690B2 · kind B2 · utility
0Cited by
4References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 27, 2020 |
| Grant date | Dec 17, 2024 |
| Priority date | — |
| Expiry date | Jul 27, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.